Nuvectis Pharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 13
- Market Cap
- $130M
- Website
- http://nuvectis.com
- Introduction
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
A Phase 1 Clinical Study of NXP900 in Subjects with Advanced Cancers
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: NXP900
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nuvectis Pharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05873686
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer
- Conditions
- Advanced Solid TumorARID1A Gene MutationOvarian Clear Cell TumorOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian CancerOvarian Clear Cell CarcinomaOvarian Endometrioid Tumor
- Interventions
- Drug: NXP800
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Nuvectis Pharma, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05226507
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Honor Health, Phoenix, Arizona, United States
🇺🇸UC San Diego Health - Moores Cancer Center, La Jolla, California, United States